TLSI Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):

TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors...

Stats
Today's Volume	5 081.00
Average Volume	41 088.00
Market Cap	296.47M
EPS	$0 ( 2024-05-15 )
Next earnings date	( $0 ) 2024-07-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.460
ATR14	$0.0900 (0.91%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-06	Hyveled Liselotte	Buy	35 000	Stock Option (right to buy)
2024-05-06	Hyveled Liselotte	Buy	0
2024-02-13	Szela Mary T	Buy	84 899	Common Stock
2024-02-13	Szela Mary T	Buy	288 750	Employee Stock Option (right to buy)
2024-02-12	Marshak Richard	Buy	63 750	Employee Stock Option (right to buy)

INSIDER POWER
18.72
Last 82 transactions
Buy: 10 589 864 \| Sell: 8 042 900

Volume Correlation

Long: -0.03 (neutral)

Short: -0.30 (neutral)

Signal:(60.829) Neutral

TriSalus Life Sciences, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

TriSalus Life Sciences, Correlation - Currency/Commodity

0.33
( neutral )

0.20
( neutral )

0.00
( neutral )

0.20
( neutral )

0.14
( neutral )

-0.16
( neutral )

TriSalus Life Sciences, Financials

Annual	2023
Revenue:	$18.51M
Gross Profit:	$15.91M (85.93 %)
EPS:	$-6.28

FY	2023
Revenue:	$18.51M
Gross Profit:	$15.91M (85.93 %)
EPS:	$-6.28

FY	2022
Revenue:	$12.40M
Gross Profit:	$10.14M (81.79 %)
EPS:	$-1.790

Financial Reports:

No articles found.

TriSalus Life Sciences, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

TriSalus Life Sciences,

TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.